NEO
NEOGENOMICS INC
- Latest sale
- $321k
- Aug 4 · Unusual
- Form 4 sales
- 121
- On record
- Form 144 notices
- 1
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineAug 15 2024
Sold 1,040 shares at $16.05 ($17k)
Olivo Alicia C, General Counsel
10b5-1 planSold 2.3% of holdings ($720k position)43,813 shares left0.4x usual sizeFiling
- 2 Form 4 saleRoutineNov 15 +92 days
Sold 5,175 shares at $15.36 ($79k)
Olivo Alicia C, General Counsel
10b5-1 planSold 12.2% of holdings ($650k position)37,129 shares left2.8x usual sizeFiling
- 3 Form 4 saleRoutineOct 16 +335 days
Sold 4,918 shares at $10.00 ($49k)
Olivo Alicia C, EVP, GC & Business Development
10b5-1 planSold 10.3% of holdings ($479k position)43,022 shares left1.9x usual sizeFiling
- 4 Form 4 saleUnusualNov 25 +40 days
Sold 20,916 shares at $12.00 ($251k)
Olivo Alicia C, EVP, GC & Business Development
10b5-1 planSold 40.2% of holdings ($624k position)31,083 shares left8.1x usual sizeFiling
- 5 Form 4 saleRoutineJan 20 +56 days
Sold 22,128 shares at $12.50 ($277k)
Stone Warren, Pres & Chief Operating Officer
10b5-1 planSold 15.4% of holdings ($1.8M position)121,631 shares leftFirst sale on recordFiling
- 6 Form 4 saleRoutineJun 9 +140 days
Sold 5,307 shares at $11.29 ($60k)
Tetrault Lynn A., Director
10b5-1 planSold 5.5% of holdings ($1.1M position)91,422 shares leftFirst sale on recordFiling
- 7 Form 4 saleRoutineJun 15 +6 days
Sold 5,307 shares at $11.10 ($59k)
Tetrault Lynn A., Director
10b5-1 planSold 5.8% of holdings ($1M position)86,115 shares leftFiling
- 8 Form 4 saleUnusualAug 4 +50 days
Sold 20,000 shares at $16.07 ($321k)
Aunan Greg D, Chief Accounting Officer
No 10b5-1 planSold 79.5% of holdings ($404k position)5,153 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales, notices and lockups (122)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Aunan Greg D | Chief Accounting Officer | Form 4 sale | 20,000 | $321k | 79.5% | Unusual | SEC |
| Jun 15, 2026 | Tetrault Lynn A. | Director | Form 4 sale | 5,307 | $59k | 5.8% | Routine | SEC |
| Jun 9, 2026 | Tetrault Lynn A. | Director | Form 4 sale | 5,307 | $60k | 5.5% | Routine | SEC |
| Jan 20, 2026 | Stone Warren | Pres & Chief Operating Officer | Form 4 sale | 22,128 | $277k | 15.4% | Routine | SEC |
| Nov 25, 2025 | Olivo Alicia C | EVP, GC & Business Development | Form 4 sale | 20,916 | $251k | 40.2% | Unusual | SEC |
| Oct 16, 2025 | Olivo Alicia C | EVP, GC & Business Development | Form 4 sale | 4,918 | $49k | 10.3% | Routine | SEC |
| Nov 15, 2024 | Olivo Alicia C | General Counsel | Form 4 sale | 5,175 | $79k | 12.2% | Routine | SEC |
| Aug 15, 2024 | Olivo Alicia C | General Counsel | Form 4 sale | 1,040 | $17k | 2.3% | Routine | SEC |
| May 15, 2024 | Olivo Alicia C | General Counsel | Form 4 sale | 1,049 | $17k | 2.3% | Routine | SEC |
| Mar 4, 2024 | Tetrault Lynn A. | Director | Form 4 sale | 6,112 | $98k | 10.9% | Routine | SEC |
| Feb 15, 2024 | Olivo Alicia C | General Counsel | Form 4 sale | 2,587 | $39k | 6.9% | Routine | SEC |
| Nov 17, 2023 | Olivo Alicia C | General Counsel | Form 4 sale | 2,669 | $49k | 6.7% | Routine | SEC |
| Nov 17, 2023 | Olivo Alicia C | Officer | Form 144 notice | 2,669 | $48k | Notice | SEC | |
| Mar 7, 2022 | Bonello William | Chief Financial Officer | Form 4 sale | 3,209 | $59k | 3.2% | Plan not stated | SEC |
| Dec 21, 2021 | McKenzie Kathryn B | Chief Financial Officer | Form 4 sale | 1,846 | $65k | 13.6% | Plan not stated | SEC |
| Nov 26, 2021 | Brown Douglas Matthew | Chief Strategy Officer | Form 4 sale | 100,000 | $3.7M | 89.6% | Unusual | SEC |
| Nov 24, 2021 | Bonello William | President, Informatics | Form 4 sale | 25,000 | $928k | 61.8% | Unusual | SEC |
| Jun 8, 2021 | Crowther Bruce K | Director | Form 4 sale | 20,734 | $860k | 29.5% | Unusual | SEC |
| Jun 3, 2021 | Cardoza George | President, Pharma Services | Form 4 sale | 200,337 | $8.1M | 53.1% | Unusual | SEC |
| May 25, 2021 | Shovlin Robert J. | President, Clinical Services | Form 4 sale | 130,604 | $5.1M | 46.5% | Unusual | SEC |
| Dec 14, 2020 | Weiss Lawrence Martin | Chief Medical Officer | Form 4 sale | 20,200 | $1M | 16.7% | Plan not stated | SEC |
| Dec 14, 2020 | Jones Steven C | Director | Form 4 sale | 70,000 | $3.6M | 6.5% | Plan not stated | SEC |
| Dec 11, 2020 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 15,000 | $750k | 37.5% | Unusual | SEC |
| Dec 7, 2020 | Jones Steven C | Director | Form 4 sale | 130,000 | $6.3M | 10.8% | Plan not stated | SEC |
| Dec 4, 2020 | Johnson Kevin C | Director | Form 4 sale | 24,683 | $1.2M | 44.3% | Unusual | SEC |
| Dec 2, 2020 | Bonello William | President, Informatics | Form 4 sale | 8,000 | $374k | 39.9% | Unusual | SEC |
| Nov 25, 2020 | Cardoza George | President, Pharma Services | Form 4 sale | 130,000 | $5.9M | 26.0% | Unusual | SEC |
| Nov 16, 2020 | Hipp Raymond R | Director | Form 4 sale | 70,000 | $3M | 51.2% | Unusual | SEC |
| Nov 16, 2020 | Van Oort Douglas M | Chairman and CEO | Form 4 sale | 340,000 | $14.3M | 12.3% | Plan not stated | SEC |
| Nov 10, 2020 | Pedulla Denise E | General Counsel | Form 4 sale | 2,262 | $95k | 3.8% | Plan not stated | SEC |
| Sep 29, 2020 | Jones Steven C | Director | Form 4 sale | 280,000 | $10.3M | 18.9% | Plan not stated | SEC |
| Sep 24, 2020 | Crowther Bruce K | Director | Form 4 sale | 10,733 | $377k | 18.8% | Plan not stated | SEC |
| Sep 10, 2020 | Jones Steven C | Director | Form 4 sale | 120,000 | $4.4M | 8.0% | Plan not stated | SEC |
| Aug 6, 2020 | Cardoza George | President, Pharma Services | Form 4 sale | 82,500 | $3.2M | 19.0% | Plan not stated | SEC |
| Aug 3, 2020 | Bonello William | President, Informatics | Form 4 sale | 22,000 | $849k | 64.6% | Unusual | SEC |
| Aug 3, 2020 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 13,000 | $510k | 34.2% | Unusual | SEC |
| Jul 30, 2020 | Shovlin Robert J. | President, Clinical Services | Form 4 sale | 81,356 | $3.1M | 35.4% | Unusual | SEC |
| Mar 4, 2020 | Shovlin Robert J. | President, Clinical Services | Form 4 sale | 98,093 | $3M | 39.3% | Unusual | SEC |
| Mar 2, 2020 | Jones Steven C | Director | Form 4 sale | 297,300 | $8.6M | 90.7% | Unusual | SEC |
| Dec 10, 2019 | McKenzie Kathryn B | Chief Accounting Officer | Form 4 sale | 8,000 | $211k | 77.9% | Unusual | SEC |
| Nov 21, 2019 | Jones Steven C | Director | Form 4 sale | 151,230 | $3.7M | 9.0% | Plan not stated | SEC |
| Nov 19, 2019 | Van Oort Douglas M | Chairman and CEO | Form 4 sale | 187,500 | $4.5M | 100.0% | Unusual | SEC |
| Nov 15, 2019 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 6,833 | $160k | 23.0% | Plan not stated | SEC |
| Nov 12, 2019 | Cardoza George | President, Pharma Services | Form 4 sale | 19,444 | $450k | 5.6% | Plan not stated | SEC |
| Nov 7, 2019 | Cardoza George | President, Pharma Services | Form 4 sale | 55,556 | $1.3M | 15.6% | Plan not stated | SEC |
| Nov 1, 2019 | Shovlin Robert J. | President, Clinical Services | Form 4 sale | 106,274 | $2.4M | 42.2% | Unusual | SEC |
| Sep 10, 2019 | Jones Steven C | Director | Form 4 sale | 2,894 | $68k | 5.9% | Plan not stated | SEC |
| Aug 30, 2019 | Jones Steven C | Director | Form 4 sale | 40,737 | $1M | 2.4% | Plan not stated | SEC |
| Aug 28, 2019 | Bonello William | Chief Strategy Officer | Form 4 sale | 17,000 | $422k | 71.6% | Unusual | SEC |
| Aug 27, 2019 | Jones Steven C | Director | Form 4 sale | 181,339 | $4.5M | 9.5% | Plan not stated | SEC |
| Aug 26, 2019 | Hipp Raymond R | Director | Form 4 sale | 16,024 | $397k | 10.7% | Plan not stated | SEC |
| Aug 26, 2019 | Johnson Kevin C | Director | Form 4 sale | 53,000 | $1.3M | 65.2% | Unusual | SEC |
| May 8, 2019 | Hipp Raymond R | Director | Form 4 sale | 150,000 | $3.4M | 52.2% | Unusual | SEC |
| May 6, 2019 | Bonello William | Chief Strategy Officer | Form 4 sale | 7,200 | $169k | 51.7% | Unusual | SEC |
| May 3, 2019 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 30,000 | $682k | 56.8% | Unusual | SEC |
| May 3, 2019 | Cardoza George | President, Pharma Services | Form 4 sale | 151,676 | $3.5M | 33.5% | Unusual | SEC |
| May 2, 2019 | Shovlin Robert J. | President, Clinical Services | Form 4 sale | 119,347 | $2.6M | 42.4% | Unusual | SEC |
| Mar 4, 2019 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 44,000 | $854k | 65.8% | Unusual | SEC |
| Feb 27, 2019 | Jones Steven C | Executive Vice President | Form 4 sale | 299,873 | $5.7M | 86.3% | Unusual | SEC |
| Feb 27, 2019 | Shovlin Robert J. | President, Clinical Services | Form 4 sale | 186,014 | $3.5M | 60.1% | Unusual | SEC |
| Feb 26, 2019 | Bonello William | Chief Strategy Officer | Form 4 sale | 60,203 | $1.1M | 100.0% | Unusual | SEC |
| Feb 26, 2019 | Hipp Raymond R | Director | Form 4 sale | 18,889 | $357k | 6.2% | Plan not stated | SEC |
| Dec 14, 2018 | GE Medical Systems Information Technologies, Inc. | Other | Form 4 sale | 10.8M | $130M | 100.0% | Unusual | SEC |
| Nov 19, 2018 | Tetrault Lynn A. | Director | Form 4 sale | 13,000 | $208k | 25.4% | Unusual | SEC |
| Nov 14, 2018 | Tetrault Lynn A. | Director | Form 4 sale | 5,000 | $81k | 8.9% | Plan not stated | SEC |
| Nov 14, 2018 | Jones Steven C | Executive Vice President | Form 4 sale | 141,127 | $2.4M | 43.4% | Unusual | SEC |
| Nov 12, 2018 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 68,333 | $1.2M | 77.4% | Unusual | SEC |
| Nov 12, 2018 | Shovlin Robert J. | President, Clinical Services | Form 4 sale | 216,493 | $3.7M | 63.7% | Unusual | SEC |
| Nov 9, 2018 | Johnson Kevin C | Director | Form 4 sale | 66,007 | $1.1M | 45.9% | Unusual | SEC |
| Nov 9, 2018 | General Electric Co | 10% owner | Form 4 sale | 4.2M | $69.8M | 27.8% | Unusual | SEC |
| Aug 1, 2018 | Jones Steven C | Executive Vice President | Form 4 sale | 203,500 | $2.8M | 8.1% | Plan not stated | SEC |
| Jun 29, 2018 | Shovlin Robert J. | President, Clinical Services | Form 4 sale | 12,941 | $170k | 24.5% | Plan not stated | SEC |
| Jun 22, 2018 | Jones Steven C | Executive Vice President | Form 4 sale | 89,688 | $1.3M | 3.5% | Plan not stated | SEC |
| Jun 19, 2018 | Jones Steven C | Executive Vice President | Form 4 sale | 160,312 | $2.1M | 5.8% | Plan not stated | SEC |
| Jun 1, 2018 | Jones Steven C | Executive Vice President | Form 4 sale | 230,533 | $2.8M | 7.7% | Plan not stated | SEC |
| May 31, 2018 | Jones Steven C | Executive Vice President | Form 4 sale | 169,467 | $2M | 5.4% | Plan not stated | SEC |
| May 29, 2018 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 65,000 | $758k | 83.0% | Unusual | SEC |
| May 15, 2018 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 13,000 | $146k | 100.0% | Unusual | SEC |
| May 10, 2018 | Ross Steven A | CIO | Form 4 sale | 81,999 | $884k | 94.8% | Unusual | SEC |
| Jun 22, 2017 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 10,723 | $91k | 100.0% | Unusual | SEC |
| Jun 5, 2017 | Ross Steven A | CIO | Form 4 sale | 70,833 | $549k | 94.0% | Unusual | SEC |
| May 26, 2017 | Balliet Jennifer | VP and Chief Culture Officer | Form 4 sale | 3,334 | $25k | 24.9% | Plan not stated | SEC |
| Mar 20, 2017 | Brodie Steven G. | President, Pharma Services | Form 4 sale | 50,000 | $397k | 75.8% | Unusual | SEC |
| Sep 23, 2016 | Albitar Maher | Chief Medical Officer | Form 4 sale | 2,800 | $24k | 4.4% | Plan not stated | SEC |
| Sep 20, 2016 | Albitar Maher | Chief Medical Officer | Form 4 sale | 105,300 | $863k | 100.0% | Unusual | SEC |
| Sep 12, 2016 | Albitar Maher | Chief Medical Officer | Form 4 sale | 60,075 | $494k | 36.3% | Unusual | SEC |
| Aug 19, 2016 | Albitar Maher | Chief Medical Officer | Form 4 sale | 370,000 | $3M | 58.4% | Unusual | SEC |
| May 27, 2016 | Van Oort Douglas M | Chairman and CEO | Form 4 sale | 481,387 | $4.2M | 22.3% | Plan not stated | SEC |
| May 18, 2016 | Ross Steven A | CIO | Form 4 sale | 18,000 | $153k | 80.0% | Unusual | SEC |
| May 9, 2016 | Ross Steven A | CIO | Form 4 sale | 15,000 | $123k | 76.9% | Unusual | SEC |
| May 2, 2016 | Jones Steven C | Executive VP of Finance | Form 4 sale | 177,745 | $1.5M | 5.3% | Plan not stated | SEC |
| Apr 29, 2016 | Ross Steven A | CIO | Form 4 sale | 112,500 | $912k | 96.2% | Unusual | SEC |
| Mar 11, 2016 | Cardoza George | Chief Financial Officer | Form 4 sale | 32,000 | $219k | 14.5% | Plan not stated | SEC |
| Mar 9, 2016 | Van Oort Douglas M | Chairman and CEO | Form 4 sale | 450,000 | $3.2M | 21.2% | Plan not stated | SEC |
| Nov 27, 2015 | Jones Steven C | Executive VP of Finance | Form 4 sale | 385,000 | $3.1M | 10.4% | Plan not stated | SEC |
| Dec 19, 2014 | Horel Robert H. | Vice President andGM PathLogic | Form 4 sale | 32,389 | $136k | 100.0% | Unusual | SEC |
| Dec 18, 2014 | Horel Robert H. | Vice President andGM PathLogic | Form 4 sale | 62,893 | $264k | 100.0% | Unusual | SEC |
| Dec 4, 2014 | Dent Michael T | Director | Form 4 sale | 11,800 | $53k | 0.8% | Plan not stated | SEC |
| Nov 26, 2014 | Cardoza George | Chief Financial Officer | Form 4 sale | 60,000 | $257k | 33.1% | Unusual | SEC |
| Nov 21, 2014 | Dent Michael T | Director | Form 4 sale | 33,200 | $150k | 2.3% | Plan not stated | SEC |
| May 22, 2014 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 100,000 | $349k | 92.2% | Unusual | SEC |
| May 19, 2014 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 10,000 | $37k | 54.2% | Unusual | SEC |
| Dec 17, 2013 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 646 | $2k | 3.4% | Plan not stated | SEC |
| Dec 12, 2013 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 5,673 | $21k | 22.9% | Plan not stated | SEC |
| Dec 11, 2013 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 20,100 | $74k | 44.8% | Unusual | SEC |
| Dec 9, 2013 | Cardoza George | Chief Financial Officer | Form 4 sale | 20,000 | $73k | 28.1% | Unusual | SEC |
| Dec 5, 2013 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 32,996 | $121k | 42.4% | Unusual | SEC |
| Dec 3, 2013 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 32,146 | $118k | 29.2% | Unusual | SEC |
| Nov 25, 2013 | Aspen Select Healthcare LP | Executive VP of Finance | Form 4 sale | 112,969 | $404k | 3.1% | Plan not stated | SEC |
| May 2, 2013 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 2,500 | $9k | 20.0% | Plan not stated | SEC |
| May 1, 2013 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 37,500 | $140k | 75.0% | Unusual | SEC |
| Apr 30, 2013 | Jones Steven C | Executive VP of Finance | Form 4 sale | 100,000 | $371k | 2.7% | Plan not stated | SEC |
| Mar 5, 2013 | Dent Michael T | Director | Form 4 sale | 300,000 | $900k | 19.6% | Unusual | SEC |
| Dec 20, 2012 | Jones Steven C | Executive VP of Finance | Form 4 sale | 641,439 | $1.8M | 8.0% | Plan not stated | SEC |
| Sep 28, 2012 | Jones Steven C | Executive VP of Finance | Form 4 sale | 60,800 | $184k | 14.1% | Plan not stated | SEC |
| Sep 28, 2012 | Dent Michael T | Director | Form 4 sale | 75,000 | $226k | 4.7% | Unusual | SEC |
| Sep 26, 2012 | Gasparini Robert P | Chief Science Officer | Form 4 sale | 3,155 | $10k | 100.0% | Unusual | SEC |
| Apr 30, 2012 | Dent Michael T | Director | Form 4 sale | 15,602 | $27k | 1.0% | Plan not stated | SEC |
| Feb 22, 2012 | Dent Michael T | Director | Form 4 sale | 70,055 | $121k | 100.0% | Unusual | SEC |
| Oct 24, 2011 | Dent Michael T | Director | Form 4 sale | 28,000 | $32k | 55.4% | Unusual | SEC |
| Jun 8, 2011 | Dent Michael T | Director | Form 4 sale | 10,000 | $14k | 16.5% | Plan not stated | SEC |
| May 18, 2011 | Smits Mark W | Chief Commercial Officer | Form 4 sale | 45,000 | $62k | 100.0% | Unusual | SEC |